Observation summary of changes in urinary protein and efficacy of Fenelidone (Keshenda) after taking it for 6 days

Finerenone (Finerenone) is a new selective mineral cortical receptor antagonist (MRA), mainly used to treat patients with chronic kidney disease (CKD) accompanied by 2 type diabetes. Its mechanism of action is by inhibiting the inflammatory and fibrotic reactions mediated by mineral cortical receptors, reducing glomerular and renal interstitial damage, thereby improving proteinuria and delaying the decline of renal function. Finelidone carries a lower risk of hyperkalemia and is better tolerated than traditional MRAs (e.g., spironolactone, eplerenone).

Clinical and observational studies have shown that some patients may experience a mild decrease in urinary protein levels after taking fenelidone for 6 days. Significant long-term renal benefits cannot usually be observed with short-term use, but it can initially reflect the protective effect of the drug on the glomerular filtration membrane. Changes in urinary protein can be evaluated by 24hour urine protein quantification or urine protein/creatinine ratio to initially determine the patient's sensitivity to drugs.

Although the observation period of 6 days is shorter, a trend improvement with fenelidone can still be found in early efficacy monitoring. Some patients experienced a slight decrease in urinary protein, while blood pressure and serum potassium levels did not change significantly, indicating that the drug was well tolerated in the short term. It should be noted that significant improvement in proteinuria with fenelinone usually requires continuous administration for weeks to months, so short-term changes are mainly used to judge the initial response and safety of the drug rather than the final efficacy.

During the initial stage of fenelidone treatment, doctors should regularly monitor urinary protein, blood pressure, electrolytes and renal function, especially blood potassium levels, to prevent potential adverse reactions. For patients whose urinary protein does not decrease significantly after short-term use of 6 days, they should not stop taking the drug easily, but should continue to observe until the recommended course of treatment. Overall, short-term use of fenelidone can reflect certain drug effect trends, but efficacy evaluation and final benefit still need to rely on mid- and long-term follow-up data.

Reference link:https://www.drugs.com